Drug Profile
MK 2248
Alternative Names: MK-2248Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Merck Sharp & Dohme
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Hepatitis-C in USA (PO)
- 01 Nov 2014 Merck Sharp & Dohme completes a phase I trial in Hepatitis C infection in USA (NCT02161510)
- 16 Jul 2014 Preclinical trials in Hepatitis C in USA (PO)